OverviewSuggest Edit

Edwards Lifesciences is a company operating as a global provider of patient-focused medical solutions for structural heart disease and critical care monitoring. The company develops heart valve therapies and manufactures heart valve systems and repair products used to replace or repair diseased or defective heart valves. It also offers hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

TypePublic
Founded1958
HQIrvine, CA, US
Websiteedwards.com
Employee Ratings4.1
Overall CultureB+

Latest Updates

Employees (est.) (Dec 2020)14,900(+8%)
Job Openings885
Revenue (FY, 2020)$4.4 B
Share Price (Sept 2021)$120.9(+2%)
Cybersecurity ratingBMore

Key People/Management at Edwards Lifesciences

Donald E. Bobo

Donald E. Bobo

Corporate Vice President, Strategy & Corporate Development
Michael A. Mussallem

Michael A. Mussallem

Chairman and Chief Executive Officer
Todd J. Brinton

Todd J. Brinton

Corporate Vice President, Advanced Technology, Chief Scientific Officer
Daveen Chopra

Daveen Chopra

Corporate Vice President, Surgical Structural Heart
Dirksen J. Lehman

Dirksen J. Lehman

Corporate Vice President, Public Affairs
Jean-Luc Lemercier

Jean-Luc Lemercier

Corporate Vice President, EMEA, Canada and Latin America
Show more

Edwards Lifesciences Office Locations

Edwards Lifesciences has offices in Irvine, Draper, Washington, Macquarie Park and in 35 other locations
Irvine, CA, US (HQ)
1 Edwards Way
Draper, UT, US
12050 Lone Peak Pkwy
Washington, DC, US
601 13th St NW #350
Macquarie Park, AU
40 Talavera Rd
Wien, AT
Vorgartenstraße 206C
Dilbeek, BE
Pontbeekstraat 4
Show all (40)

Edwards Lifesciences Financials and Metrics

Edwards Lifesciences Revenue

Embed Graph
View revenue for all periods
Edwards Lifesciences's revenue was reported to be $4.39 b in FY, 2020 which is a 0.9% increase from the previous period.
USD

Revenue (Q2, 2021)

1.4b

Gross profit (Q2, 2021)

1.0b

Gross profit margin (Q2, 2021), %

75.7%

Net income (Q2, 2021)

489.5m

EBIT (Q2, 2021)

542.1m

Market capitalization (14-Sept-2021)

75.2b

Closing stock price (14-Sept-2021)

120.9

Cash (30-Jun-2021)

1.3b

EV

74.6b
Edwards Lifesciences's current market capitalization is $75.2 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

3.7b4.3b4.4b

Revenue growth, %

8%17%1%

Cost of goods sold

939.4m1.1b1.1b

Gross profit

2.8b3.2b3.3b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

993.0m1.1b1.1b1.1b925.0m1.1b1.2b1.4b

Cost of goods sold

231.8m304.0m292.4m265.1m238.2m281.0m293.4m334.3m

Gross profit

761.2m782.9m801.6m863.6m686.8m859.9m923.2m1.0b

Gross profit Margin, %

77%72%73%77%74%75%76%76%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

818.3m714.1m1.2b1.2b

Accounts Receivable

421.6m456.9m543.6m514.6m

Prepaid Expenses

60.6m54.3m59.1m75.1m

Inventories

554.9m607.0m640.9m802.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

583.6m722.2m1.0b823.4m

Depreciation and Amortization

81.9m77.4m89.3m107.2m

Inventories

(124.0m)(65.7m)(105.4m)(120.6m)

Accounts Payable

85.2m192.5m(63.5m)(84.5m)
USDFY, 2017

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

1.9 x
Show all financial metrics

Edwards Lifesciences Operating Metrics

FY, 2017FY, 2018FY, 2019FY, 2020

Countries

100100100

Manufacturing Facilities

7777

Patents and Patent Applications

3.6 k3.9 k4.7 k
Show all operating metrics

Edwards Lifesciences Acquisitions / Subsidiaries

Company NameDateDeal Size
CAS Medical SystemsFebruary 11, 2019$100.8 m
Harpoon MedicalDecember 01, 2017$119.5 m
Valtech CardioJanuary 23, 2017$352.7 m
CardiAQ Valve TechnologiesAugust 26, 2015$348 m
BMEYEOctober 09, 2012€28.4 m
Embrella CardiovascularMarch 11, 2011$42.6 m
MyocorOctober 09, 2008
Percutaneous Valve TechnologiesJanuary 27, 2004$125 m
Whitland ResearchDecember 05, 2003$3.2 m
Edwards Lifesciences AG
Show more

Edwards Lifesciences Revenue Breakdown

Embed Graph

Edwards Lifesciences revenue breakdown by business segment: 65.1% from Transcatheter Aortic Valve Replacement, 17.4% from Surgical Structural Heart, 16.5% from Critical Care and 1.0% from Other

Edwards Lifesciences revenue breakdown by geographic segment: 57.4% from United States, 22.2% from Europe, 10.5% from Japan and 9.9% from Rest of World

Edwards Lifesciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Edwards Lifesciences Online and Social Media Presence

Embed Graph

Edwards Lifesciences Company Culture

  • Overall Culture

    B+

    85/100

  • CEO Rating

    A+

    95/100

  • Compensation

    B

    78/100

Learn more on Comparably

Edwards Lifesciences News and Updates

Stocks Gaining Momentum : Edwards Lifesciences Corporation ( NYSE : EW , Zosano Pharma Corporation ( NASDAQ : ZSAN

Stocks Gaining Momentum : Edwards Lifesciences Corporation ( NYSE : EW , Zosano Pharma Corporation ( NASDAQ : ZSAN

Global Transcatheter Heart Valve Replacement Devices Market Report 2021 Featuring Edwards Lifesciences, Medtronic, Livanova, Abbott, Boston Scientific, CryoLife

Dublin, Sept. 03, 2021 (GLOBE NEWSWIRE) -- The "Transcatheter Heart Valve Replacement Devices - Market Insights, Competitive Landscape and Market Forecast - 2026" drug pipelines has been added to ResearchAndMarkets.com's offering. The Transcatheter Heart Valve Replacement Devices (THVR) market rep…

Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equity

Edwards Lifesciences Corporation (NYSE: EW) today announced it has established a Social Impact Investment Fund to expand access to capital in underserved communities. The $100 million fund was created from Edwards’ existing investments, as a new portfolio aimed at advancing racial equity through eco…

Edwards Lifesciences Reports Second Quarter Results

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021.

Edwards Lifesciences Swings to 2Q Profit , Points to Recovery Signs

Edwards Lifesciences Swings to 2Q Profit , Points to Recovery Signs

Edwards Lifesciences Earnings Top; Medtech Leader Guides Higher

Edwards Lifesciences Earnings Top; Medtech Leader Guides Higher
Show more

Edwards Lifesciences Blogs

Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff

Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff Content Import Tue, 06/01/2021 - 16:16 Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff June 1, 2021 at 4:15 PM EDT …

Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR

Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR Content Import Tue, 05/18/2021 - 16:16 Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR May 18, 2021 at 4:15 PM EDT …

Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR

Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR Content Import Tue, 05/18/2021 - 16:16 Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR May 18, 2021 at 4:15 PM EDT T…

Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021

Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021 Content Import Tue, 04/13/2021 - 07:05 Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021 April 13, 2021 at 7:05 AM EDT This release is a backfill from a News Wire …

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

AUSTIN, Texas , Jan. 31, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards' bioprosthetic surgical aortic valve with the company's novel RESILIA tissue platform show favorable safety and hemodynamic performance

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021 Content Import Wed, 01/13/2021 - 07:05 Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021 January 13, 2021 at 7:05 AM EST This release is a backfill from a News Wi…
Show more

Edwards Lifesciences Frequently Asked Questions

  • When was Edwards Lifesciences founded?

    Edwards Lifesciences was founded in 1958.

  • Who are Edwards Lifesciences key executives?

    Edwards Lifesciences's key executives are Donald E. Bobo, Michael A. Mussallem and Todd J. Brinton.

  • How many employees does Edwards Lifesciences have?

    Edwards Lifesciences has 14,900 employees.

  • What is Edwards Lifesciences revenue?

    Latest Edwards Lifesciences annual revenue is $4.4 b.

  • What is Edwards Lifesciences revenue per employee?

    Latest Edwards Lifesciences revenue per employee is $294.4 k.

  • Who are Edwards Lifesciences competitors?

    Competitors of Edwards Lifesciences include Zimmer Biomet, Bristol-Myers Squibb and Livanova.

  • Where is Edwards Lifesciences headquarters?

    Edwards Lifesciences headquarters is located at 1 Edwards Way, Irvine.

  • Where are Edwards Lifesciences offices?

    Edwards Lifesciences has offices in Irvine, Draper, Washington, Macquarie Park and in 35 other locations.

  • How many offices does Edwards Lifesciences have?

    Edwards Lifesciences has 40 offices.